Structured Review

Tocris pf 514273 selectivity ki
Effect of CB 1 and TRPV1 antagonists application on 20:4-NAPE-induced inhibition of mEPSC frequency in naive slices. (A,C) The application of CB 1 antagonist <t>PF</t> <t>514273</t> (0.2 μM) significantly increased the frequency of the recorded mEPSC, as is evident in the native recording example (A) and the averaged data graph ( C , n = 15, *** p < 0.001 vs. control, ### p < 0.001 vs. SB 366791, one-way ANOVA on ranks, Kruskal-Wallis test, Dunn’s post hoc test). Subsequent co-application of PF 514273 (0.2 μM) and 20:4-NAPE (20 μM) did not change the mEPSC frequency compared to the antagonist pretreatment (D) . (B,C) TRPV1 antagonist SB 366791 application (10 μM) did not change the mEPSC frequency compared to the control level ( n = 11). Subsequent application of 20:4-NAPE (20 μM) in the presence of SB 366791 (10 μM) induced significant inhibition of the mEPSC frequency (B,D) . (D) The summary graph shows a comparison of 20:4-NAPE-induced inhibition with the effects of 20:4-NAPE co-application with CB 1 and TRPV1 antagonists. Data are expressed as a percentage of the pretreatment. PF 514273 prevented the 20:4-NAPE-induced inhibitory effect on mEPSC frequency, while SB 3667 did not (* p < 0.05, *** p < 0.001 vs. pretreatment (100%), Wilcoxon signed rank test; # p < 0.05 vs. co-application of PF 514273 + 20:4-NAPE, one-way ANOVA with Tukey post hoc test).
Pf 514273 Selectivity Ki, supplied by Tocris, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pf 514273 selectivity ki/product/Tocris
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
pf 514273 selectivity ki - by Bioz Stars, 2024-02
86/100 stars

Images

1) Product Images from "Inhibition of synaptic transmission by anandamide precursor 20:4-NAPE is mediated by TRPV1 receptors under inflammatory conditions"

Article Title: Inhibition of synaptic transmission by anandamide precursor 20:4-NAPE is mediated by TRPV1 receptors under inflammatory conditions

Journal: Frontiers in Molecular Neuroscience

doi: 10.3389/fnmol.2023.1188503

Effect of CB 1 and TRPV1 antagonists application on 20:4-NAPE-induced inhibition of mEPSC frequency in naive slices. (A,C) The application of CB 1 antagonist PF 514273 (0.2 μM) significantly increased the frequency of the recorded mEPSC, as is evident in the native recording example (A) and the averaged data graph ( C , n = 15, *** p < 0.001 vs. control, ### p < 0.001 vs. SB 366791, one-way ANOVA on ranks, Kruskal-Wallis test, Dunn’s post hoc test). Subsequent co-application of PF 514273 (0.2 μM) and 20:4-NAPE (20 μM) did not change the mEPSC frequency compared to the antagonist pretreatment (D) . (B,C) TRPV1 antagonist SB 366791 application (10 μM) did not change the mEPSC frequency compared to the control level ( n = 11). Subsequent application of 20:4-NAPE (20 μM) in the presence of SB 366791 (10 μM) induced significant inhibition of the mEPSC frequency (B,D) . (D) The summary graph shows a comparison of 20:4-NAPE-induced inhibition with the effects of 20:4-NAPE co-application with CB 1 and TRPV1 antagonists. Data are expressed as a percentage of the pretreatment. PF 514273 prevented the 20:4-NAPE-induced inhibitory effect on mEPSC frequency, while SB 3667 did not (* p < 0.05, *** p < 0.001 vs. pretreatment (100%), Wilcoxon signed rank test; # p < 0.05 vs. co-application of PF 514273 + 20:4-NAPE, one-way ANOVA with Tukey post hoc test).
Figure Legend Snippet: Effect of CB 1 and TRPV1 antagonists application on 20:4-NAPE-induced inhibition of mEPSC frequency in naive slices. (A,C) The application of CB 1 antagonist PF 514273 (0.2 μM) significantly increased the frequency of the recorded mEPSC, as is evident in the native recording example (A) and the averaged data graph ( C , n = 15, *** p < 0.001 vs. control, ### p < 0.001 vs. SB 366791, one-way ANOVA on ranks, Kruskal-Wallis test, Dunn’s post hoc test). Subsequent co-application of PF 514273 (0.2 μM) and 20:4-NAPE (20 μM) did not change the mEPSC frequency compared to the antagonist pretreatment (D) . (B,C) TRPV1 antagonist SB 366791 application (10 μM) did not change the mEPSC frequency compared to the control level ( n = 11). Subsequent application of 20:4-NAPE (20 μM) in the presence of SB 366791 (10 μM) induced significant inhibition of the mEPSC frequency (B,D) . (D) The summary graph shows a comparison of 20:4-NAPE-induced inhibition with the effects of 20:4-NAPE co-application with CB 1 and TRPV1 antagonists. Data are expressed as a percentage of the pretreatment. PF 514273 prevented the 20:4-NAPE-induced inhibitory effect on mEPSC frequency, while SB 3667 did not (* p < 0.05, *** p < 0.001 vs. pretreatment (100%), Wilcoxon signed rank test; # p < 0.05 vs. co-application of PF 514273 + 20:4-NAPE, one-way ANOVA with Tukey post hoc test).

Techniques Used: Inhibition

Effect of CB 1 and TRPV1 antagonists application on 20:4-NAPE-induced inhibition of mEPSC frequency under inflammatory conditions. (A,C) CB 1 antagonist PF 514273 (0.2 μM) application did not change the mEPSC frequency ( n = 10). Subsequent co-application of 20:4-NAPE (20 μM) and PF 514273 (0.2 μM) induced strong inhibition (D) . (B,C) The frequency of mEPSC did not change during the application of TRPV1 antagonist SB 366791 (10 μM, n = 11). Subsequent co-application of 20:4-NAPE (20 μM) and SB 366791 (10 μM) also did not change the mEPSC frequency significantly ( n = 11). (D) Data expressed as a percentage of pretreatment show that SB 366791 application ( n = 11) prevented the 20:4-NAPE-induced ( n = 12) inhibitory effect on mEPSC frequency under the inflammatory conditions, while PF 514273 did not ( n = 10, * p < 0.05, ** p < 0.01 versus pretreatment (100%) Wilcoxon signed rank test; # p < 0.05 vs. co-application of SB 366791 + 20:4-NAPE, one-way ANOVA with Tukey post hoc test).
Figure Legend Snippet: Effect of CB 1 and TRPV1 antagonists application on 20:4-NAPE-induced inhibition of mEPSC frequency under inflammatory conditions. (A,C) CB 1 antagonist PF 514273 (0.2 μM) application did not change the mEPSC frequency ( n = 10). Subsequent co-application of 20:4-NAPE (20 μM) and PF 514273 (0.2 μM) induced strong inhibition (D) . (B,C) The frequency of mEPSC did not change during the application of TRPV1 antagonist SB 366791 (10 μM, n = 11). Subsequent co-application of 20:4-NAPE (20 μM) and SB 366791 (10 μM) also did not change the mEPSC frequency significantly ( n = 11). (D) Data expressed as a percentage of pretreatment show that SB 366791 application ( n = 11) prevented the 20:4-NAPE-induced ( n = 12) inhibitory effect on mEPSC frequency under the inflammatory conditions, while PF 514273 did not ( n = 10, * p < 0.05, ** p < 0.01 versus pretreatment (100%) Wilcoxon signed rank test; # p < 0.05 vs. co-application of SB 366791 + 20:4-NAPE, one-way ANOVA with Tukey post hoc test).

Techniques Used: Inhibition

Similar Products

No Results Found